Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents...
Saved in:
Main Authors: | Marcia L. Moss, Dmitry Minond |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2017/9673537 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
by: Priya Tripathi, et al.
Published: (2014-01-01) -
A disintegrin and metallopeptidase domain (ADAM) 12, ADAM 17 mRNA and ADAM10 protein hold potential as biomarkers for detection of early gastric cancer
by: Sooyeon Oh, et al.
Published: (2025-01-01) -
Advancements in targeted drug delivery: A promising approach in oral cancer treatment
by: Rajkumar Prabhakaran, et al.
Published: (2024-06-01) -
Recent Advances on Bacterial Cellulose-Based Wound Management: Promises and Challenges
by: Hedaiat Moradpoor, et al.
Published: (2022-01-01) -
Evidence That ADAM17 Mediates the Protective Action of CGRP against Angiotensin II-Induced Inflammation in Vascular Smooth Muscle Cells
by: Si-yu Zeng, et al.
Published: (2018-01-01)